LUX-Breast Clinical Trial Programme Infographic

Boehringer Ingelheim

The LUX-Breast Clinical Trial Programme consists of three key clinical trials, investigating the safety and efficacy of afatinib* in patients with advanced/metastatic breast cancer. In total, an estimated 1020 patients will be enrolled into the LUX-Breast clinical trials in more than 300 locations in more than 30 countries.

If you are an investigator interested in becoming involved in one the studies and have potentially eligible patients, please visit http://clinicaltrials.gov/ct2/results?term=lux-breast for more information about the trials.

*Afatinib is an investigational compound. Its safety and efficacy have not yet been fully established.

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on